Mesalamine - Adverse effects
Research News and Information

Monday, November 23, 2009

Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis.

29 Sep 2009 BACKGROUND: 5-Aminosalicylate (5-ASA) agents are the mainstay of oral therapy for ulcerative colitis (UC). Balsalazide, a prodrug of 5-ASA, has recently been approved for the treatment of UC. OBJECTIVE: To summarize current data on balsalazide and ... Read more...

[The problems of compliance and adherence, using the example of chronic inflammatory bowel disease]

21 Jun 2009 To what extent do patients comply with their doctor's treatment recommendation, i.e. show "compliance" and "adherence" ?. The treatment of chronic diseases in particular is associated with enormous problems of adherence. Patients often take only 40 ... Read more...

[A case of mesalazine-induced lung injury improved by only discontinuation of mesalazine]

30 May 2009 We reported a case of drug-induced lung injury associated with mesalazine. A 50-year-old woman was diagnosed as having ulcerative colitis and treated with mesalazine. After administration for 1 month, the patient developed dry cough, fever and ... Read more...

Latest indexed articles for 'Mesalamine - Adverse effects'

These are the very latest articles for this heading:

• Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. 29 Sep 2009
• Mesalamine-induced multiple pulmonary cavitary nodules associated with cytoplasmic antineutrophil cytoplasmic antibody (c-ANCA). 30 Jul 2009
• [The problems of compliance and adherence, using the example of chronic inflammatory bowel disease] 21 Jun 2009
• [A case of mesalazine-induced lung injury improved by only discontinuation of mesalazine] 30 May 2009
• Encapsulated mesalamine granules (Apriso) for ulcerative colitis. 16 May 2009
• Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. 14 Apr 2009
• Reproductive issues in inflammatory bowel disease. 30 Mar 2009
• Hypereosinophilia due to mesalazine treatment. 30 Mar 2009
• Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease. 26 Mar 2009
• Mesalazine-induced aplastic anemia. Mar 2009
• [Alopecia as adverse reaction of mesalazine] 27 Feb 2009
• Renal effects of long-term treatment with 5-aminosalicylic acid. 27 Feb 2009
• [Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis] 27 Feb 2009
• Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease. 26 Feb 2009
• [Mesalazine-induced eosinophilic pneumonia in a patient with Crohn's disease] 30 Jan 2009
• Myocarditis by mesalazine with cardiac magnetic resonance imaging. 22 Jan 2009
• Comment: Mesalamine-associated hypersensitivity myocarditis in ulcerative colitis and the Kounis syndrome. 11 Jan 2009
• Mesalazine-induced interstitial nephritis. 30 Dec 2008
• Mesalamine-induced pleuritis in a patient with ulcerative colitis. 30 Dec 2008
• [Severe tubulo-interstitial nephritis secondary to 5-ASA] 21 Dec 2008

See a longer list of these articles.

Technical information about 'Mesalamine'

Definition: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)

Registry Number: 89-57-6

Descriptor UI: D019804

Alternative terms: Mesalamine; meta-Aminosalicylic Acid; meta Aminosalicylic Acid; m-Aminosalicylic Acid; m Aminosalicylic Acid; 5-Aminosalicylic Acid; 5 Aminosalicylic Acid; Mesalazine; Asacolon; Celltech Brand of Mesalamine; Ascolitin; Sanofi Synthelabo Brand of Mesalamine; Henning Berlin Brand of Mesalamine; Canasa; Salofalk; Provalis Brand of Mesalamine; Falk Brand of Mesalamine; Farmasa Brand of Mesalamine; Axcan Brand of Mesalamine; Antigen Brand of Mesalamine; Claversal; SmithKline Brand of Mesalamine; Merckle Brand of Mesalamine; Fivasa; Norgine Brand of Mesalamine; Lixacol; Schering-Plough Brand of Mesalamine; Schering Plough Brand of Mesalamine; Mesalamine Hydrochloride; Hydrochloride, Mesalamine; Mesalamine Monosodium Salt; Monosodium Salt, Mesalamine; Mesasal; GlaxoSmithKline Brand of Mesalamine; Novo-5 ASA; Novo 5 ASA; Novo5 ASA; Novopharm Brand of Mesalamine; Pentasa; Ferring Brand of Mesalamine; Yamanouchi Brand of Mesalamine; Allphar Brand of Mesalamine; Rowasa; Solvay Brand of Mesalamine; 5-Aminosalicylate; 5 Aminosalicylate; Asacol; Procter & Gamble Brand of Mesalamine; Byk Brand of Mesalamine;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Anti-Inflammatory Agents, Non-Steroidal;

Tree Number: D02.241.223.100.380.800.050.540; D02.241.511.390.700.050.500; D02.755.410.700.050.500;

History Note: 98; use MESALAMINE (NM) 1981-97